MOTIVATION
Dipeptidyl peptidase IV (DPP-IV) is a key therapeutic target for type 2 diabetes, and its inhibitory peptides are a promising class of therapeutic agents. However, the discovery of these promising drugs has been restricted, as many existing computational predictors are based on datasets that have remained st...
Zhi-Xing Zhang, Qiu Yu, Chen Yang et al.· ChemMedChem· 0 citations
Th17 cells are central drivers of autoimmune pathology, including multiple sclerosis (MS), yet the endogenous metabolic signals that shape their pathogenic differentiation remain incompletely defined. Prostaglandin D₂ (PGD2) is traditionally viewed as an extracellular mediator in allergic diseases. Here, we identify PG...
Yu-Xin Zhuang, Kawai Lei, Yan Li et al.· Signal Transduction and Targ...· 0 citations
Clinical attrition in drug development is frequently driven by suboptimal pharmacokinetic and toxicological (ADMET) properties rather than inadequate target efficacy. Accordingly, early-stage ADMET assessment has become an increasingly important component of Structure-Based Drug Design (SBDD). Here, we present empirica...
J. Encinar, Chen Yang, Raquel Fernández-Ginés et al.· Journal of Chemical Informat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.